Literature DB >> 30872154

Prevalence estimates for chronic urticaria in the United States: A sex- and age-adjusted population analysis.

Sara Wertenteil1, Andrew Strunk1, Amit Garg2.   

Abstract

BACKGROUND: Disease burden in chronic urticaria (CU) is poorly understood.
OBJECTIVE: To estimate standardized overall and sex-, age-, and race-specific prevalence estimates for CU among adults in the United States.
METHODS: A cross-sectional analysis with electronic health records data for a demographically heterogeneous population-based sample of >55 million patients across all 4 census regions.
RESULTS: The overall CU prevalence was 0.23%, or 230 CU cases/100,000 adults. The adjusted prevalence in women was 310 (95% confidence interval [CI] 307-312) cases/100,000 adults, more than twice that of men (146 [95% CI 143-148] cases/100,000 adults, P < .001). CU prevalence was highest among patients aged 40-49 years (256 [95% CI 252-261] cases/100,000 adults) and 50-59 years (246 [95% CI 242-251] cases/100,000 adults) compared with all other age groups (P < .0001). Adjusted prevalences for black (292 [95% CI 285-298] cases/100,000 adults) and other (331 [95% CI 323-338] cases/100,000 adults) patients were higher than that for white patients (262 [95% CI 260-264] cases/100,000 adults; P < .001). LIMITATIONS: Use of administrative data has the potential to underestimate burden.
CONCLUSION: There are >500,000 people estimated to have CU in the United States, most of whom are women or adults ≥40 years of age.
Copyright © 2019 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Explorys; burden of disease; chronic urticaria; population-based; prevalence; urticaria

Mesh:

Year:  2019        PMID: 30872154     DOI: 10.1016/j.jaad.2019.02.064

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  6 in total

Review 1.  Urticaria.

Authors:  Pavel Kolkhir; Ana M Giménez-Arnau; Kanokvalai Kulthanan; Jonny Peter; Martin Metz; Marcus Maurer
Journal:  Nat Rev Dis Primers       Date:  2022-09-15       Impact factor: 65.038

2.  Trends in the Cost and Utilization of Omalizumab in the Medicare Population: 2013-2017.

Authors:  Shayan Cheraghlou; Nelson Ugwu; Beverly Yu; Jeffrey M Cohen
Journal:  Yale J Biol Med       Date:  2022-06-30

3.  Natural history, prognostic factors and patient perceived response to treatment in chronic spontaneous urticaria.

Authors:  Peter Stepaniuk; Manstein Kan; Amin Kanani
Journal:  Allergy Asthma Clin Immunol       Date:  2020-07-15       Impact factor: 3.406

4.  Risk Factors for Acute Urticaria in Central California.

Authors:  Rohan Jadhav; Emanuel Alcala; Sarah Sirota; John Capitman
Journal:  Int J Environ Res Public Health       Date:  2021-04-02       Impact factor: 3.390

Review 5.  The challenges of chronic urticaria part 1: Epidemiology, immunopathogenesis, comorbidities, quality of life, and management.

Authors:  Mario Sánchez-Borges; Ignacio J Ansotegui; Ilaria Baiardini; Jonathan Bernstein; Giorgio Walter Canonica; Motohiro Ebisawa; Maximiliano Gomez; Sandra Nora Gonzalez-Diaz; Bryan Martin; Mário Morais-Almeida; Jose Antonio Ortega Martell
Journal:  World Allergy Organ J       Date:  2021-06-01       Impact factor: 4.084

6.  Efficacy of acupuncture treatment for chronic spontaneous urticaria: study protocol for a randomised controlled trial.

Authors:  Qianhua Zheng; Hui Zheng; Siyuan Zhou; Yunzhou Shi; Leixiao Zhang; Xianjun Xiao; Wei Zhang; Li Zhou; Ying Huang; Mingling Chen; Feng Zhong; Chuan Wang; Ying Li
Journal:  BMJ Open       Date:  2022-02-01       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.